Literature DB >> 1167646

Patterns of clinical response and plasma dopa levels in Parkinson's disease.

E S Tolosa, W E Martin, H P Cohen, R L Jacobson.   

Abstract

Serial determinations of plasma dihydroxyphenylalanine (dopa) in 16 Parkinson's disease patients receiving levodopa showed a negative correlation between plasma dopa levels and disability scores among patients who exhibited daily fluctuations of signs and symptoms. This suggests that the amount of levodopa delivered to the brain from the periphery is of major importance in the production of the "on-off" phenomenon. A close relationship between plasma dopa levels and abnormal involuntary movements was present in six patients. In three a striking dissociation between control of Parkinson's disease and abnormal involuntary movements was present, suggesting that in some patients these two effects are mediated through different underlying mechanisms. Administration of levodopa in such a way as to prevent both high and low levels of dopa in plasma minimizes disability in Parkinson's disease and may lessen abnormal involuntary movements in patients with the "on-off" effect.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1167646     DOI: 10.1212/wnl.25.2.177

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.

Authors:  J M Cedarbaum; M Hoey; F H McDowell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

2.  Editorial: Alternatives to levodopa.

Authors: 
Journal:  Br Med J       Date:  1976-05-15

3.  Sustained-release of levodopa: single dose study of a new formulation.

Authors:  M Gerlach; W Kuhn; T Müller; P Klotz; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.

Authors:  B Henry; J M Brotchie
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

5.  Madopar HBS and the decompensated phase of Parkinson disease.

Authors:  T Caraceni; N Nordera; E Lamperti; A Lorizio
Journal:  Ital J Neurol Sci       Date:  1989-08

6.  Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study.

Authors:  R Cantello; M Gilli; A Riccio; B Bergamasco
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-10       Impact factor: 10.154

7.  Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients.

Authors:  I Rainero; M Gilli; T De Gennaro; I Chiadò; M Delsedime; A Riccio; B Bergamasco
Journal:  Ital J Neurol Sci       Date:  1988-06

8.  "On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma.

Authors:  T Eriksson; T Magnusson; A Carlsson; A Linde; A K Granérus
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

Review 9.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 10.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.